Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Right to opt out of agreement, different specified times Right To Opt Out Of Agreement Number Of Periods Represents the number of periods with right to opt out of agreement. Award Timing Predetermined Award Timing Predetermined [Flag] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Accrued other expenses Accrued Other Expenses Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accrued interest Line of Credit Facility, Increase, Accrued Interest Purchases of short-term investments Payments to Acquire Short-Term Investments Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount License revenue License [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] REVENUES Revenue from Contract with Customer [Text Block] Number of shares of common stock issued (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock upon vesting of restricted stock units (RSUs) (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Total current taxes Current Income Tax Expense (Benefit) Adjustment to Compensation, Amount Adjustment to Compensation Amount Principal outstanding, net of unamortized debt issuance costs Debt Principal Outstanding, Net Of Unamortized Debt Issuance Costs Amount, after deduction of unamortized debt issuance costs. Percentage Concentration Risk, Percentage Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock options Share-Based Payment Arrangement, Option [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Percent Effective Income Tax Rate Reconciliation, Percent [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash, Cash Equivalent, and Short-Term Investment [Text Block] Total stockholders’ equity Balance Balance Equity, Attributable to Parent Insider Trading Policies and Procedures [Line Items] New York NEW YORK Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Authorized number of shares of common stock (in shares) Common Stock, Shares Authorized Price Range Five ExercisePriceRangeFive [Member] Represents the exercise price range of $2.74 - $3.49. Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] State and local State and Local Jurisdiction [Member] Cover [Abstract] Cover [Abstract] Maximum Maximum [Member] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Government-sponsored enterprise securities Government-Sponsored Enterprise Securities [Member] Government-Sponsored Enterprise Securities Commercial Milestones Specified Commercial Milestones [Member] Represents specified commercial milestones. Intangible assets, net Finite-Lived Intangible Assets, Net Government Assistance, Operating Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration] Government Assistance, Operating Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Debt Instrument [Line Items] Debt Instrument [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Government contracts Government Contract [Member] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company State and local Income Tax Paid, State and Local, after Refund Received [Abstract] Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Income Taxes Paid (Net of Refunds Received) Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Contractual obligations not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Amount of off-balance sheet contractual obligations subject to cancellation fees. Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Exercise Price Range [Axis] Exercise Price Range [Axis] Schedule of Expense Related to All of Our Stock-based Awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net amortization of discount on short-term investments and term loans Investment Income, Net, Amortization of Discount and Premium Lease liabilities, current portion Operating Lease, Liability, Current Document Fiscal Period Focus Document Fiscal Period Focus Intangible assets, net Intangible Assets, Net (Including Goodwill) Award Timing Method Award Timing Method [Text Block] Price Range Two ExercisePriceRangeTwo [Member] Represents the exercise price of $2.00. Award Type Award Type [Axis] Collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Stock-based Compensation Share-Based Payment Arrangement [Policy Text Block] Trading Symbol Trading Symbol Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Issuance of common stock upon exercise of options, net of shares withheld, and participation in Purchase Plan (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, City or Town Entity Address, City or Town Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Upon EMA approval of fostamatinib for treatment of chronic ITP EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpura [Member] Represents European Medicines Agency approval of fostamatinib for treatment of chronic immune thrombocytopenic purpura. Deferred tax assets, net of allowance Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] RSUs Restricted Stock Units (RSUs) [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Payments for acquisition of intangible assets Payments to Acquire Intangible Assets Outstanding (in shares) Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Unamortized debt issuance costs Debt Issuance Costs, Net Central Nervous System, Product-by-product Sales Milestone Central Nervous System, Product-by-product Sales Milestone [Member] Central Nervous System, Product-by-product Sales Milestone Capital expenditures Payments To Acquire Capital Expenditures The cash outflow associated with the acquisition of capital expenditures. Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Allowances SEC Schedule, 12-09, Allowance, Credit Loss [Member] Tennessee TENNESSEE Schedule of Revenues Disaggregated by Category Disaggregation of Revenue [Table Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Valuation allowance decreased Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Nature of Operation, Product Information, Concentration of Risk [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Blueprint Blueprint Medicines Corporation [Member] Represents Blueprint Medicines Corporation. Schedule of Estimated Future Amortization Expense of Intangible Asset Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Prepaid and other current assets Total prepaid and other current assets Prepaid Expense and Other Assets, Current Future minimum payments Maturities of Long-Term Debt [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date (Benefit from) provision for income taxes Total (benefit from) provision for income taxes/ Effective tax rate Income Tax Expense (Benefit) Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total cost Property, Plant and Equipment, Gross Cash, cash equivalents and short-term investments Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Federal Income Tax Paid, Federal, after Refund Received Collaborative payment received Proceeds from Collaborators All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred tax liabilities Deferred Tax Liabilities, Gross [Abstract] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Licensed Rights Licensed Rights [Member] Represents licensed rights. Unrecognized stock-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Estimated useful lives Property, Plant and Equipment, Useful Life Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Schedule of Weighted-Average Assumptions Relating to Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Interest expense, net Interest Income (Expense), Operating Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] PEO Total Compensation Amount PEO Total Compensation Amount Foreign Income Tax Paid, Foreign, after Refund Received [Abstract] Money market funds Money Market Funds [Member] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercised/Released (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Or Released Weighted Average Grant Date Fair Value The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were exercised or released. EPS Denominator—Diluted: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Equity Components [Axis] Equity Components [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Cost share payments to a collaboration partner Payment of cost share to collaboration partner Payment Of Cost Share To Collaboration Partner Payment of cost share to collaboration partner. Research and development tax credits Effective Income Tax Rate Reconciliation, Research And Development Credits, Amount Effective Income Tax Rate Reconciliation, Research and Development Credits, Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product sales, net Total product sales, net Product [Member] Number of segments Number of Reportable Segments Total Loans Payable Company's percentage of development costs Development Costs Cost Sharing Arrangement Percentage Percentage of development costs in cost sharing arrangement. Sales Sales [Member] Advertising Expense Advertising Cost [Policy Text Block] Entity Address, State or Province Entity Address, State or Province Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Price Range Seven ExercisePriceRangeSeven [Member] Represents the exercise price range of $3.94 - $4.18. Award purchase period Share Based Compensation Arrangement by Share Based Payment Award, Award Purchase Period Represents the purchase period for awards under the equity-based compensation plan. Individual: Individual [Axis] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Document Annual Report Document Annual Report Research and development Research and Development Expense [Member] Customer Allowance And Discount Activity [Roll Forward] Customer Allowance Activity For Prompt Payment Discounts [Roll Forward] Customer Allowance Activity For Prompt Payment Discounts Creditable advance royalty payment Creditable advance royalty payment [Member] Represents creditable advance royalty payment. Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Entity Interactive Data Current Entity Interactive Data Current Non-CNS penetrant IP NonCentralNervousSystemPenetrantIntellectualProperty [Member] Represents non-central nervous system penetrant intellectual property. Weighted-Average Remaining Contractual Life (in years) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Deferred revenue Deferred Tax Assets, Deferred Income Gross product sales GrossProduct [Member] Represents gross product. Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Delivery of drug supplies, royalty and others RoyaltyDeliveryOfDrugSuppliesAndOthers [Member] Represents royalty, delivery of drug supplies and others. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Beginning Balance Ending Balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Other assets Other Assets, Noncurrent Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Deferred revenue Contract with Customer, Liability, Current McKesson Corporation MckessonSpecialtyCareDistributionCorporation [Member] Represents McKesson Specialty Care Distribution Corporation. Prepaid and other current and non-current assets Increase (Decrease) in Prepaid Expense and Other Assets Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Unrecognized compensation cost related to purchase plan Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three FDA Approval and First Commercial Sale of Product FDA Approval And First ommercial Sale Of Product [Member] Represents FDA approval and first commercial sale of the product. Achievement of Milestone [Axis] Achievement of Milestone [Axis] Information by categories of milestones achieved. Intangible assets cost Finite-Lived Intangible Assets, Gross Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss Entity Address, Address Line One Entity Address, Address Line One Research and development Research and Development Expense Schedule of Stock Options by Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Investments [Domain] Investments [Domain] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Work in process Inventory, Work in Process, Gross Range of exercise prices, low end of the range (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit First Anniversary of the Closing Date First Anniversary Of TheClosing Date [Member] Represents the first anniversary of the closing date. Controlled Equity Offering [Table] Controlled Equity Offering [Table] Represents the information about the Controlled Equity Offering. Fair Value as of Grant Date Award Grant Date Fair Value Net operating loss carryforwards Operating Loss Carryforwards Balance at the beginning of the year Balance at end of year Customer Allowance For Prompt Payment Discounts Amount of customer allowances for prompt payment discounts. Financing component liability Product Liability Accrual, Component Amount Changes in unrecognized tax benefit Effective Income Tax Rate Reconciliation, Tax Contingency, Amount Employee related expenses Labor and Related Expense Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Company's share of development costs, limit Cumulative Share Of Development Costs Limit Amount of company's cumulative share of development costs limit under agreement. Total costs and expenses Costs and Expenses Cancelled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Fair Value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Deferred income tax benefit Deferred Income Taxes and Tax Credits Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Counterparty Name [Domain] Counterparty Name [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Medison MedisonPharmaLtd. [Member] Represents Medison Pharma Ltd. Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Release of cost share liability Release of cost share liability Release Of Cost Share Liability Revenue Recognized Release Of Cost Share Liability Revenue Recognized Investment Type [Axis] Investment Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Non-PEO NEO Non-PEO NEO [Member] Outstanding as of December 31, 2025 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Prepaid and Other Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Sale of Stock [Axis] Sale of Stock [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax All Award Types Award Type [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year One Equity Awards Adjustments Equity Awards Adjustments [Member] Advertising expense Advertising Expense Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Commercial and license agreements CommercialAndLicenseAgreement [Member] Represents commercial and license agreements. Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Net income (loss) per share Net Income Loss Per Share [Abstract] Net income loss per share abstract. Compensation Amount Outstanding Recovery Compensation Amount Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Expected dividend yield Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Accrued compensation Increase (Decrease) in Employee Related Liabilities Collaborative arrangement potential payment percent Collaborative Arrangement, Potential Payment Percent Collaborative Arrangement, Potential Payment Percent Additions to revenue reserves Provision related to current period sales SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Foreign tax effect (Indian withholding tax) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Cancelled and forfeited (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Cancelled And Forfeited Number of equity instruments cancelled and forfeited during the period. Employee Stock Employee Stock [Member] Revenues: Revenues [Abstract] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] No of individuals Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax 2026 Long-Term Debt, Maturity, Year One Potential payments Collaborative Arrangement Potential Payments Maximum amount of contingent payments under collaborative arrangement. Financial Instruments [Domain] Financial Instruments [Domain] Performance Shares Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Royalty Royalty [Member] Inventories Inventory, Net Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name One Month Secured Overnight Financing Rate (SOFR) One Month Secured Overnight Financing Rate (SOFR) [Member] One Month Secured Overnight Financing Rate (SOFR) US customers UnitedStatesCustomers [Member] Represents customers in the United States. DEBT Debt Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current Unrecognized tax benefits decrease, evaluation of prior orphan drug credits Unrecognized Tax Benefits Decreases Resulting From Evaluation Of Prior Orphan Drug Credits Amount of decrease in unrecognized tax benefits resulting from evaluation of prior orphan drug credits. Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Price Range Four ExercisePriceRangeFour [Member] Represents the exercise price range of $2.21 - $2.72. Lilly Lilly [Member] Lilly Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Tax Period [Axis] Tax Period [Axis] Foreign Current Foreign Tax Expense (Benefit) Controlled Equity Offering Controlled Equity Offering [Line Items] Represents information about the Controlled Equity Offering. Diluted (in shares) Weighted-average shares outstanding and common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted Segment Reporting Segment Reporting, Policy [Policy Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Small Business Entity Small Business Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding State and local Current State and Local Tax Expense (Benefit) Document Transition Report Document Transition Report Schedule of Customer Revenues (as a Percentage of Gross Revenues) Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Total Purchase Consideration In Connection With Asset Acquisition Asset Acquisition, Contingent Consideration [Table Text Block] Underlying Securities Award Underlying Securities Amount Government and Other Rebates Government and Other Rebates [Member] Represents government and other rebates. Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] INCOME TAXES Income Tax Disclosure [Text Block] Collaborative arrangement payment percent Collaborative Arrangement, Milestone Payment, Percent Collaborative Arrangement, Milestone Payment, Percent Closing purchase price payment related to asset acquisition Payment for Contingent Consideration Liability, Financing Activities Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Specified Development Events Specified Development Events [Member] Represents specified development events. Reverse Stock Split Stockholders Equity Reverse Stock Split [Policy Text Block] Disclosure of accounting policy for reverse stock split arrangement. Lease liability Increase (Decrease) in Operating Lease Liability Product-by-product Sales Milestone Product-by-product Sales Milestone [Member] Product-by-product Sales Milestone Stock options by exercise price Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] NET INCOME (LOSS) PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Product and Service [Axis] Product and Service [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Variable operating lease expense Variable Lease, Cost Total revenues Revenue from contract with customer, excluding assessed tax Revenue from Contract with Customer, Excluding Assessed Tax Other assets Inventory Reported As Other Assets Amount of inventory reported as other assets. Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total purchase consideration Asset Acquisition, Consideration Transferred Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Rezlidhia Rezlidhia [Member] Rezlidhia Restricted cash Restricted Cash [Member] Restricted Cash Deferred compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Aggregate intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Current liabilities: Liabilities, Current [Abstract] Orphan drug and research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Level 1 Fair Value, Inputs, Level 1 [Member] (Gain) loss on sale and disposal of fixed assets Gain (Loss) on Disposition of Assets Stock-based compensation expense related to stock-based awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Accounts receivable, net Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Cash, Cash Equivalents and Short-Term Investments Cash and Cash Equivalents and Short Term Investments [Policy Text Block] Disclosure of accounting policy for cash and cash equivalents and short-term investments. Total state and local Income Tax Paid, State and Local, after Refund Received Auditor Location Auditor Location Asset Acquisition [Table] Asset Acquisition [Table] Other comprehensive income: Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract] Price Range Six ExercisePriceRangeSix [Member] Represents the exercise price range of $3.54 - $3.92. Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Strategic collaboration agreement with CONNECT StrategicCollaborationAgreementWithConnect [Member] Represents strategic collaboration agreement with CONNECT, an international collaborative network of pediatric cancer centers. Income taxes paid Total income taxes paid Income Taxes Paid, Net 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Principal outstanding Long-Term Debt, Gross Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Accrued compensation Employee-related Liabilities, Current Total minimum payments required Lessee, Operating Lease, Liability, to be Paid 2018 Equity Incentive Plan Equity Incentive Plan 2018 [Member] Represents the 2018 Equity Incentive Plan of the entity. Schedule of Fair Value and Gross Unrealized Losses of Our Investments Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Expiration Date Trading Arrangement Expiration Date Other current and long-term liabilities Increase (Decrease) in Other Operating Liabilities 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Five Product Information [Line Items] Product Information [Line Items] Property and equipment, net Property, Plant and Equipment, Net Net unrealized gain on short-term investments Net change in unrealized gain on short-term investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories and Cost of Product Sales Inventory, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Kamil Ali-Jackson [Member] Kamil Ali-Jackson Development and regulatory milestones by CNS disease products Central Nervous System, Specified Development And Regulatory Milestone [Member] Represents development and regulatory milestones by central nervous system disease products. Federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Provision for prompt payment discount Customer Allowance For Prompt Payment Discounts Period Increase Increase during the period in customer allowances for prompt payment discounts. Cancellation fees under agreements with contract manufacturers Cancellation Fees Under Agreements With Contract Manufacturers Amount of cancellation fees under agreements with contract manufacturers. Financial Instrument [Axis] Financial Instrument [Axis] Deferred tax assets Deferred Tax Assets, Gross [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Executive Category: Executive Category [Axis] Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent State and local, net of federal income tax effect* Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Current Fiscal Year End Date Current Fiscal Year End Date Gross Unrealized Losses Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant India INDIA Options Outstanding Share Based Compensation Shares Authorized under Stock Option Plans Exercise Price Range Outstanding Options [Abstract] Share Based Compensation Shares Authorized under Stock Option Plans Exercise Price Range Outstanding Options [Abstract] SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACTS Collaborative Arrangement Disclosure [Text Block] Cash Cash [Member] Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Long-term portion of loans payable, net Long-term portion of loans payable, net Loans Payable, Noncurrent Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Corporate bonds and commercial paper Corporate Bonds and Commercial Paper [Member] Corporate Bonds and Commercial Paper Prepaid research and development costs Prepaid Research And Development Cost Prepaid Research And Development Cost DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Description and Accounting Policies [Text Block] Balance at the beginning of the year Balance at the end of the year Unrecognized Tax Benefits Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average shares used in computing net income (loss) per share Weighted Average Number of Shares Outstanding, Diluted [Abstract] Contract revenues from collaborations Total revenues from collaborations Contract revenues from collaborations [Member] Represents contract revenues from collaborations. 2027 Long-Term Debt, Maturity, Year Two Strategic collaboration agreement with MD Anderson StrategicCollaborationAgreementWithMdAnderson [Member] Represents strategic collaboration agreement with MD Anderson. Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Measure: Measure [Axis] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Specified Product Launch Events Specified Product Launch Events [Member] Represents specified product launch events. Acquisition-related liabilities Asset Acquisition, Contingent Consideration, Liability, Noncurrent Open Market Sales Agreement Open Market Sales Agreement [Member] Open Market Sales Agreement Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Cost of product sales Cost of Product and Service Sold Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Entity Tax Identification Number Entity Tax Identification Number Prepaid inventory Prepaid Inventory Prepaid Inventory Common stock, weighted average price of shares (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure Asset Acquisition [Axis] Asset Acquisition [Axis] Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Cardinal Health, Inc. Cardinal Health Inc. [Member] Cardinal Health Inc. Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Revenue reserves and refund liability Revenue Reserves And Refund Liability Represents the increase (decrease) during the reporting period in the aggregate amount of revenue reserves and refund liability. Price Range One ExercisePriceRangeOne [Member] Represents the exercise price range of $1.68 - $1.96. Entity Public Float Entity Public Float Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Weighted-average time to maturity (in days) Cash Equivalents and Available For Sale Securities, Weighted Average Maturity Period Represents the weighted-average period of maturity of cash equivalents and available-for-sale debt securities. Security Exchange Name Security Exchange Name Foreign Income Tax Paid, Foreign, after Refund Received Asset acquisition, expected price Asset Acquisition, Price of Acquisition, Expected Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Other current liabilities Other Liabilities, Current Statement [Line Items] Statement [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Additional shares approved (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Common Stock Common Stock [Member] Achievement of Certain Near-Term Regulatory Milestone Achievement Of Certain Near-Term Regulatory Milestone [Member] Represents achievement of a certain near-term regulatory milestone. Price Range Three ExercisePriceRangeThree [Member] Represents the exercise price range of $2.02 - $2.14. Dilutive effect of stock options, RSUs and shares under Purchase Plan (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Outside clinical trial related expenses Outside Clinical Trial Related Expenses Amount of outside clinical trial related expenses. Statistical Measurement [Domain] Statistical Measurement [Domain] Government Contracts Government Contract Policy [Policy Text Block] Disclosure of accounting policy for government contract. Award offering period Share-Based Compensation Arrangement By Share-based Payment Award, Consecutive Offering Period Represents the offering period for awards under the equity-based compensation plan. Accounts payable Increase (Decrease) in Accounts Payable Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic (in dollars per share) Earnings Per Share, Basic Schedule of Future Minimum Payments Schedule of Line of Credit Facilities [Table Text Block] Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance US treasury bills US Treasury Bill Securities [Member] Changes in unrecognized tax benefit Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Total net deferred tax assets Deferred Tax Assets, Gross Schedule of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Schedule of Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalent, and Investment [Table Text Block] Revenue, remaining performance obligation Revenue, Remaining Performance Obligation, Amount Kissei Kissei Pharmaceutical Co., Ltd. [Member] Kissei Pharmaceutical Co., Ltd. Final payment fee (in percent) Debt Instrument, Redemption Prepayment Fee Percent Debt Instrument, Redemption Prepayment Fee Percent Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Revenue recognized Collaborative Arrangement Revenue Recognized Represents the revenue recognized during the period under the terms of sponsored research and license agreements. Total stock-based compensation expense Share-Based Payment Arrangement, Expense Tax Period [Domain] Tax Period [Domain] Current assets: Assets, Current [Abstract] Cancelled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Total liabilities and stockholders’ equity Liabilities and Equity Antidilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Other, net Deferred Tax Assets, Other Accrued commercial expenses Accrued Commercial Expenses Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accounting Policies [Abstract] Accounting Policies [Abstract] Exercised/Released (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Or Released In Period The number of equity-based payment instruments, excluding stock (or unit) options, that were exercised or released during the reporting period. Single reportable segment Single reportable segment [Member] Represents a single reportable segment. Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Government contracts revenue Government Assistance, Operating Income, Increase (Decrease) Pay vs Performance Disclosure [Line Items] IN-LICENSING AND ACQUISITION Business Combination [Text Block] Number of Shares (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Reduction in prompt payment discount Customer Allowance For Prompt Payment Discounts Period Decrease Decrease during the period in customer allowances for prompt payment discounts. Other long-term liabilities Other Liabilities, Noncurrent Range of exercise prices, high end of the range (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Upfront fee Collaborative Arrangement Upfront Payment Amount of collaborative arrangement upfront payment. Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Name Measure Name Upfront payment Collaborative Arrangement Upfront Fee Received Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement. Schedule of Cash Equivalents and Short-Term Investments Including Securities With Unrealized Gains and Losses Unrealized Gain (Loss) on Investments [Table Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Principal amount (Tranches 1, 2, 3 and 4) Long-Term Debt Legal Entity [Axis] Legal Entity [Axis] Total assets Assets 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Depreciation and amortization expense Depreciation And Amortization Expense Expense recognized in the current period that allocates the cost of assets to periods that benefit from use of the assets. Income Taxes Income Tax, Policy [Policy Text Block] Operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Other segment items Segment Reporting, Other Segment Item, Amount Intangible assets, estimated useful life (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Capitalized research and development expenses Deferred Tax Assets Capitalized Research and Development Expenses Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development expenses. Concentration Risk Type [Axis] Concentration Risk Type [Axis] INVENTORIES Inventory Disclosure [Text Block] 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash, Cash Equivalents, and Short-Term Investments [Abstract] Cash, Cash Equivalents, and Short-Term Investments [Abstract] Increase in right-of-use assets and lease liability Operating lease right-of-use asset and lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] State and local, net of federal income tax effect* Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Forma Forma Therapeutics Holdings Inc [Member] Represents Forma Therapeutics Holdings, Inc. Schedule of (Benefit From) Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Plan Name [Axis] Plan Name [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] PEO PEO [Member] Interest income Investment Income, Interest Income Tax Paid, by Individual Jurisdiction [Line Items] Income Tax Paid, by Individual Jurisdiction [Line Items] Federal UNITED STATES Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Number of active equity plans Number Of Active Equity Plans Represents the number of active equity plans of the Company. Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accumulated Deficit Retained Earnings [Member] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Achievement Of Milestone [Domain] Achievement Of Milestone [Domain] Different categories of achievement of milestones. Amount due to collaboration partner Due To Collaboration Partner Amount due to collaboration partner. Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Fair Value Investments, Fair Value Disclosure Product and Service [Domain] Product and Service [Domain] Potential milestone payments Potential Milestone Payment Obligations Amount of potential milestone payment obligations. Customer Concentration Risk Customer Concentration Risk [Member] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Income Tax Paid, by Individual Jurisdiction [Table] Income Tax Paid, by Individual Jurisdiction [Table] Revenue reserves and refund liability Contract with Customer, Refund Liability, Current City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Net proceeds from term loan financing Proceeds from Long-Term Lines of Credit First Commercial Sale First Commercial Sale [Member] Represents first commercial sale. Investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Total operating lease expense Lease, Cost Selling, general and administrative Selling, General and Administrative Expenses [Member] Schedule of Components of Operating Lease Expense Lease, Cost [Table Text Block] Federal Deferred Federal Income Tax Expense (Benefit) Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Auditor Name Auditor Name Earliest Tax Year Earliest Tax Year [Member] Development and regulatory milestones by non-CNS disease products Non-Central Nervous System, Specified Development And Regulatory Milestone [Member] Non-Central Nervous System, Specified Development And Regulatory Milestone Commercial related expenses Commercial Related Expenses Amount of commercial related expenses. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Specified Regulatory Events Specified Regulatory Events [Member] Represents specified regulatory events. Schedule of Customer Allowances for Prompt Payment Discounts Customer Allowance For Prompt Payment Discounts [Table Text Block] Tabular disclosure of customer allowances for prompt payment discounts. Restricted cash reported within other assets Restricted Cash Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] EPS Numerator: Earnings Per Share Reconciliation [Abstract] Others Other Assets, Current Additional paid-in capital Additional Paid in Capital, Common Stock Entity [Domain] Entity [Domain] Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activity Grifols GrifolsS.a. [Member] Represents Grifols, S.A. Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Total (benefit from) provision for income taxes/ Effective tax rate Effective Income Tax Rate Reconciliation, Percent Decrease related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Fixed operating lease expense Operating Lease, Cost Plan Name [Domain] Plan Name [Domain] Remaining weighted-average recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Liquidity Liquidity And Capital Resources [Policy Text Block] Disclosure of accounting policy for liquidity and capital resources. Exercised/Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Less: valuation allowance Valuation allowance, deferred tax assets Deferred Tax Assets, Valuation Allowance Schedule of Cash and Cash Equivalents and Available For Sale Securities [Line Items] Schedule of Cash and Cash Equivalents and Available For Sale Securities [Line Items] Schedule of Cash and Cash Equivalents and Available For Sale Securities [Line Items] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Fair Value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Federal Current Federal Tax Expense (Benefit) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Options Exercisable Share Based Compensation Shares Authorized under Stock Option Plans Exercise Price Range Exercisable Options [Abstract] Share Based Compensation Shares Authorized under Stock Option Plans Exercise Price Range Exercisable Options [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortization expense Amortization of Intangible Assets Leases Lessee, Leases [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Headquarters office space sublease, South San Francisco, California Headquarters office space sublease, South San Francisco, California [Member] Represents Headquarters office space sublease in South San Francisco, California. Deferred income tax asset Deferred Income Tax Assets, Net Acquisition payment Closing purchase price Payments to Acquire Productive Assets Depreciation and amortization Depreciation, Depletion and Amortization Product Financing Arrangement Product Financing Arrangement [Member] Finished goods Inventory, Finished Goods, Gross Accounts Receivable Accounts Receivable [Policy Text Block] Foreign tax effect (Indian withholding tax) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Arrangement Duration Trading Arrangement Duration Research and development tax credits Effective Income Tax Rate Reconciliation, Research And Development Credits, Percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development credits. Segments [Axis] Segments [Axis] Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Release Of Share Cost Liability Release Of Share Cost Liability [Member] Release Of Share Cost Liability STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Assets Assets [Abstract] Credit Facility [Axis] Credit Facility [Axis] Maturities of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Maximum value of shares available under equity offering Maximum Available Under Controlled Equity Offering Maximum value of shares available for sale under a controlled equity offering agreement. SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACTS SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACTS [Abstract] Corporate Collaborations Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cancelled and forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value FAIR VALUE Fair Value Disclosures [Text Block] Credit Facility [Domain] Credit Facility [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Royalty payment as a percentage of net sales Royalty Payment As Percentage Of Net Sales Represents royalty payment as a percentage of net sales. Long-term portion of lease liabilities Operating Lease, Liability, Noncurrent Entity Voluntary Filers Entity Voluntary Filers Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Regulatory Milestones Regulatory Milestones [Member] Represents regulatory milestones. Audit Information [Abstract] Audit Information COMMITMENTS AND CONTINGENCIES Commitments Contingencies and Guarantees [Text Block] Entity Registrant Name Entity Registrant Name Collaborative Arrangement Collaborative Arrangement [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Consultants and third-party services Consultants And Third Party Services Expense Amount of expense for consultants and third-party services. All states representing less than five percent of total State and Local Tax Jurisdiction, Other [Member] Contingent payments due to collaborative agreements Contingent Payments Under Agreement Represents additional contingent payments by entities. Adjustment related to prior period sales SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Number of segments Number of Operating Segments Corporate bonds and commercial paper CorporateBondSecuritiesAndCommercialPaper [Member] This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount) and unsecured promissory note (generally negotiable) that provides institutions with short-term funds. Schedule of Loans Payable Schedule of Debt [Table Text Block] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inducement Plan Inducement Plan [Member] Represents information pertaining to the Inducement Plan. Gavreto Gavreto [Member] Gavreto Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Principal payments of term loans Repayments of Long-Term Lines of Credit Restatement Determination Date: Restatement Determination Date [Axis] Issuance of common stock upon exercise of options, net of shares withheld, and participation in Purchase Plan Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Foreign Deferred Foreign Income Tax Expense (Benefit) Accounts Receivable Accounts Receivable [Member] Interest expense Interest Expense, Debt Name Trading Arrangement, Individual Name Credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current Alabama ALABAMA Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Name Awards Close in Time to MNPI Disclosures, Individual Name Reported as: Loans Payable, Current and Noncurrent [Abstract] Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Funding commitment Other Commitment ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Asset Acquisition [Line Items] Asset Acquisition [Line Items] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Vested and expected to vest as of December 31, 2025 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Shares Available For Grant Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Outstanding Roll Forward [Abstract] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Foreign Tax Jurisdiction Foreign Tax Jurisdiction [Member] Auditor Firm ID Auditor Firm ID Segments [Domain] Segments [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cash payments Variable Lease, Payment Inventories Increase (Decrease) in Inventories Loans payable, net, current portion Loans Payable, Current Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment fostamatinib fostamatinib [Member] Represents fostamatinib. Shares Available For Grant Share Based Compensation Options And RSUs [Member] Represents share based compensation options and RSUs. Revenue Recognition Revenue [Policy Text Block] Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 Preferred Stock, Value, Issued ocadusertib ocadusertib [Member] RIPK1 inhibitor for the treatment of non-central nervous system (non-CNS) diseases. All Executive Categories All Executive Categories [Member] Schedule of Components of Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively Common Stock, Value, Issued Short-term investments Short-Term Investments Commitments Commitments and Contingencies Accrued research and development Increase (Decrease) in Accrued Research and Development Liability Represents the increase (decrease) during the reporting period in the aggregate amount of research and development expenses incurred but not yet paid. Collaboration partners Collaboration partners [Member] Represents collaboration partners. Weighted-Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price EPS Denominator—Basic: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Number of purchase periods per award offering period Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Purchase Periods PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount OTHER BALANCE SHEET COMPONENTS Supplemental Balance Sheet Disclosures [Text Block] Schedule of Product Revenue Allowance and Reserve Categories SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Revenues: Revenue from Contract with Customer [Abstract] Schedule of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Dr. Reddy's Dr.ReddysLaboratoriesLtd. [Member] Represents Dr. Reddy's Laboratories, Ltd. Acquisition related liabilities Asset Acquisition, Contingent Consideration, Liability, Current All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Name Forgone Recovery, Individual Name Contractual term of the option Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Right-of-use assets Increase Decrease Right Of Use Assets Amount of increase or decrease in right-of-use assets. Chargebacks, Discounts and Fees Chargebacks, Discounts and Fees [Member] Represents chargebacks, discounts and fees. Net proceeds from issuance of common stock from equity plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised ESPP purchase price of common stock, percent of market price Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Weighted-Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Exercisable as of December 31, 2025 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Amended Lilly Agreement Amended Lilly Agreement [Member] Represents the amended Lilly Agreement. Net income (loss) per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Amount of tax credit carryforward Tax Credit Carryforward, Amount Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Reported as: Inventory And Inventory Reported As Other Assets [Abstract] Inventory And Inventory Reported As Other Assets Exercised/Released (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Sublicense revenue fee Sublicense revenue fee [Member] Represents sublicense revenue fee. Award Timing Disclosures [Line Items] Development and Regulatory Milestones Development And Regulatory Milestones [Member] Represents development and regulatory milestones. Schedule of Inventories Schedule of Inventory, Current [Table Text Block] STOCKHOLDERS' EQUITY Equity [Text Block] State and local Deferred State and Local Income Tax Expense (Benefit) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Total other current liabilities Other Accrued Liabilities, Current Returns Sales Returns and Allowances [Member] Schedule of (Benefit From) Provision for Income Taxes and Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Reductions in accounts receivable Credit or payments made during the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Adoption Date Trading Arrangement Adoption Date Base Rate Base Rate [Member] Potential tiered royalties (as a percent) Potential Tiered Royalty Percentage The percentage of potential tiered royalties. Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Customer [Axis] Customer [Axis] Income (loss) from operations Operating Income (Loss) Accrued research and development Accrued Research and Development Liability Current Represents the carrying value as of the balance sheet date of research and development costs that are incurred but not billed to the entity as of the end of the period. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Line of Credit Line of Credit [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Contractual obligations due in one year, not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Due Within One Year Amount of off-balance sheet contractual obligations subject to cancellation fees to be paid in next fiscal year following current fiscal year. Milestone revenue DevelopmentMilestones [Member] Represents development milestones. Discounts and allowances Discounts and allowances [Member] Represents discounts and allowances. Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Delivery of drug supply for commercialization OneTimeDeliveryOfDrugSupplyForCommercialization [Member] Represents a one-time delivery of drug supply for commercialization. Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Others Deferred Tax Liabilities, Other Statement [Table] Statement [Table] Total deferred taxes Deferred Income Tax Expense (Benefit) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Balance (in shares) Balance (in shares) Shares, Issued Variable Rate [Domain] Variable Rate [Domain] Contract with customer, liability Contract with Customer, Liability All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Acquisition-related liabilities Fair Value of Assets Acquired Termination Date Trading Arrangement Termination Date Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Schedule of Stock Options and RSUs Activity, and Shares Available For Grant Under Our Equity Incentive Plans Share-Based Payment Arrangement, Option, Activity [Table Text Block] Tax positions subject to interest or penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Schedule of Financial Assets Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Agreement opt-out right, exercise period Agreement Opt Out Right Exercise Term Period of time of agreement opt-out right, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Schedule of Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Collaboration period Collaboration Term Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Exercise Price Range [Domain] Exercise Price Range [Domain] Segment Reporting [Abstract] Segment Reporting [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Costs and expenses: Less: Costs and Expenses [Abstract] Contractual obligations due within two to three years, not included in financial statements Off Balance Sheet Contractual Obligations Subject To Cancellation Fees Due In Second And Third Year Amount of off-balance sheet contractual obligations subject to cancellation fees to be paid in second and third fiscal years following current fiscal year. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount STOCK-BASED COMPENSATION Stock Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Total Inventory And Inventory Reported As Other Assets Amount of inventory and inventory reported as other assets. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Use of Estimates Use of Estimates, Policy [Policy Text Block] Number of Shares (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Insider Trading Arrangements [Line Items] Cancelled and forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Raw materials Inventory, Raw Materials, Gross Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table] Schedule of Cash and Cash Equivalents and Available For Sale Securities [Table] Schedule of cash and cash equivalent balances, excluding any restricted cash balances, and available-for-sale securities. Total liabilities Liabilities Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Granted (in shares) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Granted Number of equity instruments granted during the period. Financing liability interest accretion discount rate (in percent) Financing Liability Interest Accretion Discount Rate Rate applied to the undiscounted amount of financing liability. Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Increase related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Knight KnightTherapeuticsInternationalSa [Member] Represents Knight Therapeutics International SA. Weighted Intrinsic Value (in thousands) Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract] n/a Kentucky KENTUCKY Variable Rate [Axis] Variable Rate [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Fair Value Debt Securities, Available-for-Sale Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Cencora Inc. CencoraInc [Member] Represents Cencora Inc.